Here are the S-3 shelf registrations from Unicycive Therapeutics, Inc. (UNCY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow UNCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNCY filings page.
Unicycive Therapeutics, Inc. is registering up to $150,000,000 of securities on a shelf registration, including up to $50,000,000 of common stock that may be sold under a Sales Agreement with Guggenheim Securities, LLC.
Subsequent to March 31, 2026, pursuant to the Sales Agreement, the Company sold 1,693,000 shares of common stock at an average price of $7.34 per share for net proceeds of approximately $11.2 million. Shares of common stock issued and outstanding were 27,393,027 as of June 5, 2026. The prospectus describes multiple distribution methods and states that specific terms for any offering will be provided in a prospectus supplement.
Separately, the Company disclosed regulatory progress for its oxylanthanum carbonate NDA: the FDA accepted a resubmission as a Class II complete response with a PDUFA target action date of June 29, 2026.